Related Experiment Video
Updated: Sep 26, 2026

Testing the Role of Multicopy Plasmids in the Evolution of Antibiotic Resistance
Published on: May 2, 2018
Gram-positive resistance: challenge for the development of new antibiotics
1Departamento de Microbiología, Ramón y Cajal Hospital, Madrid, Spain.
Abstract:
The incidence of infections caused by multidrug-resistant Gram-positive organisms is increasing despite advances in antibacterial therapy over the last 20 years. As the pathogens causing these infections are frequently resistant to most currently available antibacterials, they are extremely difficult to treat. Problematic pathogens include strains of Streptococcus pneumoniae resistant to beta-lactams and macrolides, viridans group streptococci resistant to beta-lactams and aminoglycosides, enterococci resistant to vancomycin and teicoplanin and highly resistant to penicillins and aminoglycosides, and Staphylococcus aureus resistant to methicillin, other beta-lactams, macrolides, lincosamides and aminoglycosides. Other important pathogens include Streptococcus pyogenes resistant to macrolides (and suspected to be resistant to penicillin), macrolide-resistant streptococci of groups B, C, and G, coagulase-negative staphylococci resistant to beta-lactams, aminoglycosides, macrolides, lincosamides and glycopeptides, multiresistant strains of Listeria and Corynebacterium and Gram-positive anaerobes, such as Peptostreptococcus and Clostridium, resistant to penicillins and macrolides. Thus, there is an urgent need for new antibacterial agents that are able to overcome multidrug-resistant mechanisms. The novel semisynthetic injectable streptogramin quinupristin/dalfopristin offers the prospect of effective treatment against many of the above pathogens.
Insights
Multidrug-resistant Gram-positive infections are rising, posing treatment challenges. A new streptogramin, quinupristin/dalfopristin, shows promise for combating these difficult-to-treat pathogens.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Background:
- The incidence of infections caused by multidrug-resistant Gram-positive organisms is increasing.
- These infections are difficult to treat due to widespread resistance to existing antibacterial therapies.
- Key problematic pathogens include resistant strains of Streptococcus pneumoniae, enterococci, and Staphylococcus aureus.
Purpose of the Study:
- To highlight the urgent need for novel antibacterial agents effective against multidrug-resistant Gram-positive pathogens.
- To introduce quinupristin/dalfopristin as a potential therapeutic option.
Main Methods:
- Review of current literature on multidrug-resistant Gram-positive infections.
- Identification of key resistant pathogens and their resistance profiles.
- Introduction of a novel semisynthetic injectable streptogramin.
Main Results:
- Identified numerous multidrug-resistant Gram-positive pathogens, including Streptococcus pneumoniae, enterococci, Staphylococcus aureus, and others.
- Documented resistance to various antibiotic classes such as beta-lactams, macrolides, aminoglycosides, and glycopeptides.
- Highlighted quinupristin/dalfopristin as a promising agent against these resistant strains.
Conclusions:
- There is a critical need for new antibacterial agents to address the growing threat of multidrug-resistant Gram-positive infections.
- Quinupristin/dalfopristin represents a novel therapeutic prospect for treating infections caused by a range of challenging multidrug-resistant Gram-positive organisms.
Related Concept Videos
Antibiotic Selection
Development of Antibiotic Resistance
Production of Antibiotics
Microbiota Modulation by Antibiotics
Mechanism of Antibiotic Resistance in MRSA
Clinical Significance of Antibiotic Resistance

